JP6550833B2 - urinal - Google Patents

Description

  The present invention relates to a urinal that forms a sealed water with urine.

By supplying water every time after use, flush type urinals that maintain hygiene are widespread. Human urine contains bacteria, and if urine remains in a bowl or the like of a urinal after use, bacteria in the urine further proliferate over time. Furthermore, by decomposing urea in urine and generating ammonia, ammonia odor and urine stone (solid materials such as calcium phosphate and magnesium phosphate derived from urine-containing components) are generated. For this reason, in a general flush-type urinal, the urine remaining in the bowl is washed away by discharging water to the bowl of the urinal.

  In addition, in this conventional flush toilet, the water is discharged into the bowl, so that the water flows into the trap connected downstream of the bowl, and the stored urine is replaced with the water and discharged. doing. Furthermore, the urine remaining in the drain pipe connected downstream of the trap is washed away by the water supplied from the bowl through the trap. Thereafter, the discharge of water is finished in a state where the inside of the trap is filled with water. As a result, the urine remaining in the bowl, etc., is washed away before the bacteria in the urine grow significantly, suppressing the generation of ammonia and the generation of urinary stones, preventing the generation of odors and clogging of drainage pipes due to urinary stones. ing. The water filling the trap acts as a seal and prevents backflow of odor from the drain. Since only water is present in the trap after cleaning, even if the sealing water in the trap volatilizes and diffuses into the toilet room where the urinal is installed, the volatile components do not cause odor.

  With respect to equipment using such water, in recent years, in response to rising environmental awareness, water saving performance is required. High water saving performance is also required for the above-described flush toilets, and efforts are being made to reduce the amount of water used after use.

  As an example of a urinal corresponding to a request for saving water, a non-flush type urinal having a trap as disclosed in JP-T-2007-518005 (Patent Document 1) is known. A general flush toilet supplies water every time after use and uses water stored in the trap as sealed water, whereas a non-flush type urinal with a trap disclosed in JP-T-2007-518005 In the toilet bowl, water is not basically supplied after use, and urine stored in the trap is used as sealing water.

When the urine stored in the trap is used as sealing water, ammonia volatiles due to decay of the urine and diffusion into the toilet room, and urine stones are generated in the trap and in the pipe It is a concern to do. With respect to this concern, in the trap shown in JP-A-2007-518005, the problem is solved by installing a medicine on the trap or in the vicinity of the connection between the trap and the pipe. An agent such as citric acid is placed on the trap, and the agent dissolved by contact with urine flows into the trap together with the urine. Further, a drug such as citric acid is disposed at a position where urine is discharged into the pipe, and the drug dissolved by the contact is configured to flow into the pipe together with the urine.

Japanese Patent Publication No. 2007-518005 gazette

However, non-washing urinals as described in JP-T-2007-518005 do not flow water after use. Therefore, the drug dissolves only when urine is applied to the drug when the urinal is used. Therefore, when the urinal frequency of use is low, it becomes difficult for the medicine to flow into the trap unit. As a result, the urine in the trap is easily rotted, and the generation of an ammonia odor or urine stone in the trap unit or piping is easily generated.

As a method of preventing the formation of urinary calculus in the trap unit, there is a method of placing a drug and a microbial preparation in the trap unit. It is considered that the drug and the microbial preparation can be stably dissolved in the trap unit by arranging the drug and the microbial preparation in the trap unit and immersing in urine. However, as the dissolution of the drug progresses, the volume of the drug decreases and the pH in the trap unit increases. As a result, there is a problem that the activity of the microbial preparation is reduced. In addition, depending on the type of drug, there is a problem that the microorganism contained in the microbial preparation is killed by contact between the drug and the microbial preparation, and the effect of the microbial preparation can not be obtained.

Therefore, the present invention uses a specific drug and a microorganism preparation to prevent the microorganism preparation from being killed by the medicine, and further, the generation of an ammonia smell from the inside of the trap unit and the urine in the trap unit and in the piping. It aims to prevent the occurrence of stones in the long run.

In order to achieve the above object, the present invention provides a urinal having a trap unit that forms a sealed water by urine, wherein a microbial preparation is disposed at a position in contact with the urine, and the trap unit is saturated. A solid drug containing an acid having a solubility of 20 g / 100 ml or less is disposed, and the microbial preparation and the drug are disposed so as not to be in contact with each other.

  According to the present invention, it is possible to prevent the generation of ammonia odor from the inside of the trap unit and the generation of urinary stones in the trap and the piping in the long term.

It is the schematic which shows an example of the urinal which can be used by this invention. It is sectional drawing of FIG. It is a sectional view of a trap unit concerning an embodiment of the present invention. It is the schematic of the chemical | medical agent which concerns on embodiment of this invention. It is the schematic of the chemical | medical agent which concerns on embodiment of this invention. It is the schematic of the trap unit which concerns on embodiment of this invention. It is the schematic of the trap unit which concerns on embodiment of this invention. It is a figure showing the result of an example.

  Hereinafter, the present invention will be described in detail.

(urinal)
The urinal according to the present invention is a urinal having a trap unit that forms a sealed water by urine, wherein a microbial preparation is disposed at a position in contact with the urine, and the saturation solubility is 20 g / 100 ml in the trap unit. A solid drug containing the following acid is disposed, and the microorganism preparation and the drug are disposed so as not to contact each other.

First, a urinal US which can be used in the present invention will be described with reference to FIGS. FIG. 1 is a schematic view showing a front view of the urinal US. The urinal shown here is merely an example, and the urinal of the present invention is not limited thereto.

The urinal body 10 is installed with its back surface in contact with a wall WL such as a toilet room. The urinal body 10 is formed of a material and method that can be formed into any shape such as pottery and resin material.

The urinal body 10 has a bowl portion 103 and a trap unit 30 that forms sealed water with urine. The bowl portion 103 is a portion that receives urine discharged by the user in a standing posture. The bowl portion 103 has a standing wall portion 104 and a bottom portion 105. The standing wall portion 104 is a portion that faces the user in the stool and directly receives the urine, and is a wall-shaped portion that extends vertically and horizontally. A bottom opening 106 is formed in the bottom portion 105. The bottom surface portion 105 is a portion for guiding urine received by the standing wall portion 104 and flowing downward to the bottom surface opening portion 106 which is a drainage port, and is a floor-like portion extending longitudinally and laterally. The urine guided to the bottom opening 106 by the bottom part 105 passes through the trap unit 30 from the bottom opening 106 and is discharged to the drain pipe WT outside the bowl part 103. The trap unit 30 used in the present invention will be described later.

As the urinal body 10, one having the nozzle cover 101, the human body detection sensor 102 and the hygiene maintenance device 20 can be used. An example of the preferable aspect in case the urinal main body 10 has these is demonstrated below.

The nozzle cover 101 is a cover for covering a nozzle unit 202 and a bowl drying fan 203 described later. The nozzle unit 202 and the bowl drying fan 203 are preferably disposed above the urinal body 10. Therefore, it is preferable that the nozzle cover 101 is also disposed above the urinal body 10.

  The human body detection sensor 102 is a sensor for detecting a user who uses the urinal US. The human body detection sensor 102 is preferably provided on the back side near the center of the bowl portion 103. The human body detection sensor 102 is preferably a sensor using a microwave. The human body detection sensor 102 transmits the standing wall portion 104 and irradiates the microwave, and the reflected wave that is reflected and returned from the user's body indicates that the user is in use or is finished using the urinal It is preferable that it can detect that it has left the US.

The hygiene maintenance device 20 can use what has the control unit 201, the nozzle unit 202, and the bowl drying fan 203. The hygiene maintenance device 20 is preferably provided on the back side of the urinal body 10. The control unit 201 outputs control signals for driving the nozzle unit 202 and the bowl drying fan 203.

The nozzle unit 202 is preferably provided above the upright wall portion 104 of the bowl portion 103 and discharges the liquid agent supplied from the control unit 201 toward the inside of the bowl portion 103. When the nozzle unit 202 discharges the liquid agent to the bowl portion 103, it is possible to suppress the generation of an ammonia odor and urinary calculus that originate from the urine present on the surface of the bowl portion 103. The liquid agent contains a chemical solution that suppresses generation of ammonia odor and urinary calculus, which originates from urine present on the surface of the bowl portion 103. It is preferable that a thin plate-like nozzle cover 101 is provided on the front surface of the nozzle unit 202, and the nozzle unit 202 is covered so as not to be seen by the user to improve the design.

The bowl drying fan 203 is preferably provided above the standing wall 104 of the bowl 103 and is covered by the nozzle cover 101. By driving the bowl drying fan 203, the bowl portion 103 can be dried by blowing air into the bowl portion 103.

(Trap unit)
The trap unit used in the present invention will be described with reference to FIG. As shown in FIG. 3, the trap unit 30 has a body portion 301 and a bottom surface 302.

  The trap unit 30 is provided below the bottom opening 106 which is a drainage port. The trap unit 30 has an opening through which urine excreted from the bottom opening 106 flows. Further, the trap unit 30 has a trunk portion 301 for storing the urine that has flowed in. The trap unit 30 is configured to store the inflowing urine and form sealed water by the urine. A discharge port is provided in the body of the trap unit 30, and urine that can not be stored in the trap unit 30 is discharged from the discharge port. In the trap unit 30, it is preferable that a urine volume sufficient to immerse the drug 31 in urine is stored, and for that reason, it is preferable that the discharge port be provided on the upper side of the trunk. Urine drained from the drain is drained to the drain WT. By sealing the urine in this manner, the backflow of odor from the drainage pipe WT connected downstream of the trap unit 30 is prevented. The trap unit 30 is inserted and installed in the bottom opening 106 and is configured to be replaceable. Since the trap unit 30 can be replaced, urine stones are generated in the trap unit 30, and even if a drainage failure occurs, the drainage performance can be restored by replacing the trap unit 30.

  Examples of the shape of the trap unit 30 include a cylinder, a triangular prism, and a quadrangular prism. For example, when the shape of the trap unit 30 is a cylinder, the portion formed by the side surface of the cylinder is the body portion 301 in the present invention, and the circle that is the bottom surface of the cylinder is the bottom surface 302 in the present invention. When the shape of the trap unit 30 is a cylinder, the medicine 31 can be easily placed in the trap unit 30.

The material constituting the trap unit 30 is not particularly limited as long as it is insoluble in water, has strength as a structure, and is resistant to an acid. Specific materials include resins and pottery. As the resin, known resins such as polypropylene (PP), methyl polymethacrylate (PMMA), polycarbonate (PC), polyethylene (PE), polyvinyl alcohol (PVA), polylactic acid, epoxy resin, and polyester resin can be used. .

Further, in the trap unit 30, a guide 303 for disposing the medicine 31 or the microbial preparation may be provided. The guide 303 is for holding the medicine 31 and the microorganism preparation in the trap unit 30 and is configured so that the medicine 31 and the microorganism preparation can be arranged on the guide 303. The guide 303 is preferably provided on the inner wall of the body portion 301 of the trap unit 30. Specific examples of the guide 303 include a configuration in which several convex portions are provided on the inner wall of the body portion 301 of the trap unit 30 and a configuration in which convex portions are provided so as to cover the inner periphery of the inner wall of the trap unit 30. It can be mentioned. Further, the guide 303 is preferably provided near the bottom of the trap unit 30 in order to maximize the size of the medicine 31 that can be disposed in the trap unit 30.

The guide 303 is preferably configured such that urine flows smoothly through the trap unit 30. For example, the structure which provided the communicating hole for urine to pass in the guide 303 is mentioned. As a specific example of the configuration, a configuration in which a hole communicating the protrusion is provided in the above-described protrusion may be mentioned. The number and size of the holes can be determined in consideration of the size of the drug 31 or the microbial preparation to be placed and the amount of urine flowing in the trap unit 30. When a hole is provided in the guide 303, the medicine 31 and the microorganism preparation are arranged so as not to block the hole provided in the guide 303. By providing a hole in the guide 303, urine that has flowed into the trap unit 30 enters under the medicine 31 through the hole in the guide 303, or urine that exists under the medicine 30 passes through the hole in the guide 303. It becomes possible to discharge from the discharge port provided in the trap unit 30.

  A specific configuration of the guide will be described with reference to FIG. In FIG. 3, a guide 303 is provided near the bottom of the trap unit 30. The guide 303 is a convex portion that covers the inner circumference of the inner wall of the trunk portion 301 of the trap unit 30. A medicine 31 is placed on the guide 303. In this case, by providing the holes in the guide 303, the urine flowing into the trap unit 30 passes under the medicine 31 through the holes in the guide 303, and the urine present under the medicine 30 becomes the guide 303. You may enable it to discharge | emit from the discharge port provided in the trap unit 30 through a hole.

In the present invention, the urine stored in the trap unit 30 is preferably maintained at a pH of 3 or more and 8 or less. By setting the pH to 3 or more, corrosion of the pipe WT can be prevented. Moreover, the activity of a microbial formulation can be maintained by making pH into 8 or less. As a result, non-volatile ammonium ions (NH ₄ ⁺ ) can be prevented from being converted to volatile ammonia (NH ₃ ), and ammonia can be prevented from diffusing into the air. Further, in the present invention, it is more preferable to keep the pH in the trap unit at 3 or more and 7 or less. By adjusting the pH to 7 or less, it becomes possible to suppress the production of urine stone.

(Drug)
In the trap unit 30 of the present invention, a solid medicine 31 containing an acid having a saturation solubility of 20 g / 100 ml or less is disposed. In the present invention, the saturated solubility refers to the saturated solubility measured at 25 ° C. Thereby, even if the drug 31 dissolves in the urine in the trap unit 30, it is possible to prevent the microbes contained in the urine from being killed by the influence of the drug 31. In addition, it is possible to prevent the medicine from being completely melted in the trap unit 30 in a short period of time and to maintain the performance for a long period of time.

The shape of the drug 31 used in the present invention may be a cylinder, a triangular prism, a square prism, or the like, and is not particularly limited. In the case of a cylinder, it is easy to arrange in the trap unit 30.

A specific example of the drug used in the present invention is shown in the figure. FIG. 4 is a square pole drug. FIG. 5 shows a cylindrical drug.

In the present invention, the medicine 31 has an upper surface 33, a bottom surface 34 that faces the upper surface 33, and an outer surface 32 that connects the outer periphery of the upper surface and the bottom surface, and at least one of the upper surface 33, the bottom surface 34, and the outer surface 32. It is preferable that the groove | channel or the dent 35 which forms the space where urine enters in the inside of a chemical | medical agent is formed in one surface. A specific example is shown in FIG. In the medicine 31, a recess may be formed on both the top surface 33 and the bottom surface 34, and a through hole in which both recesses communicate with each other may be formed. Thus, as the drug 31 comes into contact with urine and dissolves, the surface area of the drug in contact with urine gradually increases, so that the dissolution rate of the drug 31 can be kept constant.

Since the trap unit 30 is sealed with urine, the drug 31 disposed in the trap unit 30 is immersed in the urine. Therefore, regardless of the frequency of use of the urinal, the drug 31 is in contact with urine and the drug 31 is considered to be dissolved, unless the drug 31 dissolves and disappears by contact with urine. Thereby, generation | occurrence | production of ammonia odor and generation | occurrence | production of the urine stone in the trap unit 30 or the piping WT can be suppressed.

(Material of drug)
The drug 31 used in the present invention contains an acid. When the medicine 31 contains an acid, the activity of urease present in the trap unit 30 is suppressed, and urea is hardly decomposed into ammonia. Thereby, generation | occurrence | production of ammonia can be suppressed. Even if ammonia is generated, the ammonia can be neutralized, so that the pH in the trap unit can be kept low.

The saturated solubility of the acid contained in the drug 31 is 20 g / 100 ml or less. Thereby, even if the drug is dissolved in urine, it is possible to prevent the microorganisms contained in the urine from dying. More preferably, it is 10 g / 100 ml or less. This makes it possible to prevent the drug from being completely dissolved in the trap unit in a short time, and to maintain the pH in the trap unit low for a long time. In addition, the saturated solubility of the acid contained in the drug 31 is preferably 0.1 g / 100 mL or more. Thus, even if ammonia is generated in the trap unit, it is possible to neutralize the generated ammonia.

In the present invention, preferred acids include L-ascorbic acid, DL-mandelic acid, oxalic acid, succinic acid, adipic acid, picric acid, uric acid, phthalic anhydride, phthalic acid, fumaric acid, p-hydroxybenzoic acid, benzoic acid. And one or more selected from the group consisting of edetic acid. More preferably, one or more selected from the group consisting of phthalic anhydride, phthalic acid, fumaric acid and benzoic acid can be used. The saturated solubility of all the acids is 20 g / 100 ml or less, and the generation of ammonia can be suppressed for a long time in the trap unit while suppressing the death of the microorganism contained in the microorganism preparation.

It is preferable that the chemical | medical agent 31 contains a disinfectant as a material which suppresses the production | generation of urine stone. By containing the germicide, it is possible to kill various bacteria contained in the urine and to suppress the generation of ammonia. When only a bactericidal agent is used as a material for suppressing the formation of urinary calculus, it is preferable that the saturated solubility is 20 g / 100 ml or less, similarly to the acid. This makes it possible to prevent the drug from being completely dissolved in the trap unit in a short period of time.

As a material of the drug 31 used in the present invention, a surfactant, a fragrance and the like may be additionally contained. By including the flavor, even if the ammonia odor is generated, masking of the odor becomes possible.

(Microbial preparation)
In the present invention, in order to prevent the generation of ammonia odor in the trap unit and the generation of urinary stones in the trap unit and in the piping, the drug 31 containing an acid and the microbial preparation 40 are used in combination.

The microorganism contained in the microorganism preparation 40 used in the present invention is not particularly limited as long as it has ammonia-assimilating properties. Specifically, it is a kind selected from the group consisting of Bacillus, Paracoccus, and Thiosfella. The above can be used.

  When the drug 31 containing an acid and the microbial preparation 40 come into contact with each other, the microorganisms contained in the microbial preparation 40 die due to the influence of the acid. Therefore, in the present invention, the drug 31 and the microbial preparation 40 are arranged not to be in contact with each other.

  In the present invention, the microbial preparation 40 is placed in contact with the urine of the urinal user. Specifically, it is preferably disposed in the trap unit 30 or above the bottom opening 106 of the urinal. Thereby, the microorganisms contained in the microorganism preparation come in contact with the urine, flow into the trap unit 30, and dissolve in the urine. Therefore, it is possible to assimilate the ammonia generated in the trap unit 30 and suppress the amount of ammonia in the trap unit 30. As a result, it is possible to suppress the generation of ammonia odor and urinary calculus. When the drug 31 and the microorganism preparation 40 are arranged in the trap unit, the drug 31 is arranged on the bottom surface 302 of the trap unit 30 as shown in FIG. 7 and the microorganism preparation 40 is placed on the guide 303 provided in the trap unit 30. It is preferable to arrange so that the drug 31 and the microbial preparation 40 do not come into contact with each other. In this case, the guide 303 is preferably provided so as not to contact the drug 31. Thereby, it arrange | positions in the trap unit 30 so that the chemical | medical agent 31 and the microorganism preparation 40 may not contact. More preferably, the guide 303 is provided in the vicinity of the upper surface of the trap unit 30. As a result, even when a large drug 31 that occupies most of the volume of the trap unit 30 is placed, the drug 31 and the microbial preparation 40 can be placed in the trap unit 30 so as not to be in contact with each other.

  When the microbial preparation 40 is disposed on the bottom opening 106 of the urinal, since the drug 31 and the microbial preparation 40 are not in contact with each other, death of the microbe contained in the microbial preparation can be suppressed. Further, in the trap unit 30, the drug 31 suppresses the increase in pH. Therefore, the microorganisms contained in the microorganism preparation 40 that has flowed into the trap unit 30 in contact with urine can grow, and ammonia odor and urine stone can be prevented from being generated.

(Combination with adjuvant drugs)
In the present invention, an auxiliary drug may be used in combination separately from the drug 31 and the microbial preparation 40 used in the present invention. The auxiliary drug is not particularly limited as long as it does not interfere with the effect of the drug 31 used in the present invention. Materials that can be included in the adjunct agents include surfactants, fragrances, Bacillus subtilis, deodorants, coloring agents, emulsifying solubilizers for oily components, chelating agents, extenders, solubility modifiers, bleaching agents Water repellents, fillers, pH adjusters, thickeners, drug stability improvers, moldability improvers, inorganic builders, organic builders, enzymes and the like. The surfactant may, for example, be an anionic surfactant, a cationic surfactant, an amphoteric surfactant or a nonionic surfactant. Examples of the fragrances include plant fragrances, animal fragrances, and synthetic fragrances. A material to be used can be appropriately selected according to the purpose of using the auxiliary drug. The adjunct can be obtained by mixing selected materials and molding them into the desired shape. The shape of the auxiliary drug is not particularly limited as long as it can be disposed in the trap unit 30. The auxiliary drug may be disposed anywhere in the trap unit 30 as long as it is disposed so as not to interfere with the effects of the drug 31 and the microorganism preparation 40 used in the present invention. For example, the bottom surface 302 in the trap unit 30 may be disposed so as not to be in contact with the drug 31 or the microbial preparation 40 used in the present invention.

The present invention will be specifically described based on the following examples, but the present invention is not limited to these examples.

(Example)
Saturation solubility of acid contained in the drug when the microbe contained in the microbial preparation is killed by contact between the medicine and the microbial preparation in the trap unit when the urinal has not been used for a long time, such as at night Was evaluated. Specific test conditions are shown below. As a drug containing an acid having a specific saturated solubility, 25 mL of physiological saline in which citric acid was dissolved at a specific concentration shown in Table 1 was used. Bacillus bacteria adjusted to 5 × 10 ⁶ were used as microorganisms. Bacillus bacteria were added to physiological saline, and left at normal temperature for 20 hours, and the number of viable Bacillus bacteria after standing for 20 hours was examined. The number of viable Bacillus bacteria was appropriately determined by diluting viable bacteria, mixing with a standard agar medium, and culturing at 36 ° C. for 24 hours. Thereafter, the number of colonies was counted, and the number of viable bacteria per mL was calculated from the number of colonies. The results of the test are shown in Table 1 and FIG. In FIG. 8, the horizontal axis represents citric acid concentration (g / 100 mL), and the vertical axis represents the number of viable Bacillus bacteria (cfu / mL). As a result, Bacillus bacteria were alive up to 20 g / 100 mL. When it became 20 g / 100 mL or more, the viable count of Bacillus bacteria decreased, and when it became 30 g / 100 mL or more, Bacillus bacteria were not detected.

US: Urinal WL: Wall of toilet room WT: Piping 10: Urinal body 101: Nozzle cover 102: Human body detection sensor 103: Bowl portion 104: Standing wall portion 105: Bottom portion 106: Bottom opening 20: Sanitary maintenance device 201 : Control unit 202: Nozzle unit (liquid agent discharge means)
203: bowl drying fan 30: trap unit 301: body part 302: bottom surface 303: guide 31: drug 32: side surface 33: top surface 34: bottom surface 35: groove or recess 40: microbial preparation

Claims (6)

In a urinal with a trap unit that forms a sealed water with urine,
Microbial preparations are arranged at positions that come into contact with the urine,
In the trap unit, a solid medicine containing an acid having a saturation solubility of 20 g / 100 ml or less is disposed on a guide provided in the trap unit or disposed on the bottom surface of the trap unit. Yes,
A urinal characterized in that the microbial preparation and the drug are arranged not to be in contact with each other.
The urinal according to claim 1, wherein the microbial preparation is arranged in the trap unit or above the bottom opening of the urinal.   The urinal according to claim 1 or 2, wherein the medicine is disposed on a bottom surface of the trap unit, and the microorganism preparation is disposed on a guide provided in the trap unit. The acid is selected from L-ascorbic acid, DL-mandelic acid, oxalic acid, succinic acid, adipic acid, picric acid, uric acid, phthalic anhydride, phthalic acid, fumaric acid, p-hydroxybenzoic acid, benzoic acid and edetic acid The urinal according to any one of claims 1 to 3, wherein it is at least one selected from the group consisting of   The urinal according to any one of claims 1 to 4, wherein the microorganism contained in the microorganism preparation is at least one selected from the group consisting of Bacillus, Paracoccus, and Thiosfera. The urinal according to any one of claims 1 to 5, wherein the drug or the microbial preparation has a groove or a recess that forms a space into which urine can enter.

Images